ReNeuron Group plc (ReNeuron), a UK-base adult stem cell company, has signed a contract with Angel Biotechnology Holdings plc (Angel Biotechnology). As per the agreement, Angel Biotechnology will manufacture clinical-grade ReN001 stem cell lots for ReNeuron's Phase I clinical trial with its ReN001 therapy in disabled stroke patients. Regulatory approval for this trial was granted earlier this year.
Michael Hunt, chief executive officer of ReNeuron, said: We are pleased to have extended our collaborative arrangements with Angel by way of this critical manufacturing contract. Angel has proven ability in the manufacture of advanced biologics to the requisite quality standards. As a contract manufacturer based in Scotland, they are also well-placed to serve the needs of ReNeuron’s ground-breaking Phase I clinical trial with ReN001 in stroke, to be undertaken at Glasgow’s Southern General Hospital once ethics approval has been obtained for the trial.